StockData
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. (GLUE) stock

GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07+0.00 (0.00%)

Close on Nov 18, 2026Market cap $773.79MP/E –Yield –

Monte Rosa Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Monte Rosa Therapeutics's pe ratio was 82.1× on Jan 30, 2026.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jan 30, 202682.1×+19.4
2025Dec 31, 202562.7×–

More Monte Rosa Therapeutics figures

See a number that looks wrong?